Literature DB >> 6278963

Prevention of phenylbutazone ulcer in the rat by glucose: role of a glycoprivic receptor system.

W A Mersereau, E J Hinchey.   

Abstract

The mechanism by which the extragastric administration of phenylbutazone (PBZ) and other nonsteroid anti-inflammatory drugs induce a vagally mediated gastric hypercontractile response and ulceration is unknown. Glucose administration has been reported to protect the rat and the monkey from the ulcerogenic action of aspirin. It was postulated that by uncoupling oxidative phosphorylation PBZ might stimulate an energy-sensitive receptor system that results in the gastric contractile response. Glucose feeding or intravenous infusion was seen to prevent or abolish the gastric contractile response to the intraileal injection of 22.5 mg of PBZ in cervical-sectioned rats with miniature gastric balloons. Glucose treatment also significantly reduced ulceration and hemorrhage. Fructose infusion was somewhat less effective. Mannitol infusion had no effect on the PBZ-induced gastric contractile activity, and all animals developed severe ulceration and hemorrhage. Blood glucose levels fell significantly in starved rats treated with PBZ. Glucose feeding and glucose or fructose infusion prevented or reduced this effect. It is suggested that by alleviating the "glucoprivic state" induced by PBZ glucose abolishes the gastric contractile response and prevents ulceration and hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6278963     DOI: 10.1152/ajpgi.1982.242.4.G429

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

1.  Placebo-controlled comparison of piroxicam-beta-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans.

Authors:  L Santucci; S Fiorucci; S Chiucchiù; A Sicilia; L Bufalino; A Morelli
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

2.  Glucocorticoids are Gastroprotective under Physiologic Conditions.

Authors:  Ludmila Filaretova
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

3.  Gastric motility is an important factor in the pathogenesis of indomethacin-induced gastric mucosal lesions in rats.

Authors:  S Ueki; K Takeuchi; S Okabe
Journal:  Dig Dis Sci       Date:  1988-02       Impact factor: 3.199

Review 4.  Gastroprotective action of glucocorticoid hormones during NSAID treatment.

Authors:  L P Filaretova; T T Podvigina; T R Bagaeva; A Tanaka; K Takeuchi
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

5.  Effects of gastric distension and prostaglandin on acid ethanol-induced mucosal lesions in the rat.

Authors:  K Takeuchi; H Nishiwaki; N Hara; S Okabe
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

6.  Genetic and histological aspects of stomach lesions induced by systemic injection of phenylbutazone in the rat.

Authors:  P Driscoll; P Kugler
Journal:  Experientia       Date:  1984-09-15

7.  Inhibition of gastric motor activity by 16,16-dimethyl prostaglandin E2. A possible explanation of cytoprotection.

Authors:  K Takeuchi; Y Nobuhara
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

8.  Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility.

Authors:  Koji Takeuchi; Akiko Tanaka; Yujiro Hayashi; Yoshiaki Kubo
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

9.  Effects of parenteral diclofenac sodium on upper gastrointestinal motility after food in man.

Authors:  G Bassotti; G Bucaneve; C Betti; L Patoia; E Baratta; V Maresca; M A Pelli; A Morelli; A Del Favero
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Influences of urethane anesthesia on indomethacin-induced gastric mucosal lesions in rats. Relation to blood glucose levels.

Authors:  K Takeuchi; H Niida; T Ohuchi; S Okabe
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.